Results 41 to 50 of about 168,862 (349)

Targeting S100A9-mediated inflammation: a novel therapeutic approach for CLL

Blood Advances
: Chronic lymphocytic leukemia (CLL) presents challenges in treatment despite advancements in targeted therapies, often facing resistance or relapse. Chronic inflammation plays a significant role in CLL biology, with heightened inflammatory responses and
Angimar Uriepero-Palma, Maria Elena Márquez, Eugenia Payque, Melanie Mediavilla-Varela, Wael Gamal, Kamira Maharaj, John Powers, Julio Chavez, Erika Eksioglu, Sandra Sernbo, Florencia Palacios, Juliana Querol-Rivas, Claudia Ortega, Rita Uria, Gimena Dos Santos, Carolina Oliver, Ana Inés Landoni, Eva Sahakian, Pablo Oppezzo, Javier Pinilla-Ibarz   +19 more
doaj   +1 more source

Hematopoietic (stem) cells—The elixir of life?

FEBS Letters, EarlyView.
The aging of HSCs (hematopoietic stem cells) and the blood system leads to the decline of other organs. Rejuvenating aged HSCs improves the function of the blood system, slowing the aging of the heart, kidney, brain, and liver, and the occurrence of age‐related diseases.
Emilie L. Cerezo, Jonah Anderson, Emilie Dinh Vedrenne, Noël Yeh Martín, Jette Lengefeld   +4 more
wiley   +1 more source

Chronic lymphocytic leukemia

Annals of Oncology, 2010
The management of chronic lymphocytic leukemia (CLL) is currently undergoing a profound change. First, several new drugs have been approved (fludarabine, bendamustine and two monoclonal antibodies, alemtuzumab and rituximab). In addition, novel monoclonal antibodies targeting CD20, CD23, CD37 or CD40, as well as drugs designed to interfere with central
Michael, Hallek, Natali, Pflug
openaire   +2 more sources

PYCR1 inhibition in bone marrow stromal cells enhances bortezomib sensitivity in multiple myeloma cells by altering their metabolism

Molecular Oncology, EarlyView.
This study investigated how PYCR1 inhibition in bone marrow stromal cells (BMSCs) indirectly affects multiple myeloma (MM) cell metabolism and viability. Culturing MM cells in conditioned medium from PYCR1‐silenced BMSCs impaired oxidative phosphorylation and increased sensitivity to bortezomib.
Inge Oudaert, Lauren van den Broecke, Osman Aksoy, Judith Lind, Sonia Vallet, Arne Van der Vreken, Gamze Ates, Ann Massie, Ken Maes, Kim De Veirman, Elke De Bruyne, Karin Vanderkerken, Klaus Podar, Eline Menu   +13 more
wiley   +1 more source

Generation of a poor prognostic chronic lymphocytic leukemia-like disease model: PKCα subversion induces up-regulation of PKCβII expression in B lymphocytes

Haematologica, 2015
Overwhelming evidence identifies the microenvironment as a critical factor in the development and progression of chronic lymphocytic leukemia, underlining the importance of developing suitable translational models to study the pathogenesis of the disease.
Rinako Nakagawa, Milica Vukovic, Anuradha Tarafdar, Emilio Cosimo, Karen Dunn, Alison M. McCaig, Ailsa Holroyd, Fabienne McClanahan, Alan G. Ramsay, John G. Gribben, Alison M. Michie   +10 more
doaj   +1 more source

Invariant NKT cells contribute to chronic lymphocytic leukemia surveillance and prognosis [PDF]

, 2017
Chronic lymphocytic leukemia (CLL) is characterized by the expansion of malignant CD5(+) B lymphocytes in blood, bone marrow and lymphoid organs. CD1d-restricted invariant Natural Killer T (iNKT) cells are innate-like T lymphocytes strongly implicated in
Azzimonti, Laura, Bellone, Matteo, Bertilaccio, Maria Teresa, Caligaris Cappio, Federico, Capri, Miriam, Casorati, Giulia, de Lalla, Claudia, Delfanti, Gloria, Dellabona, Paolo, DI NAPOLI, Arianna, Doglioni, Claudio, Franceschi, Claudio, Ghia, Paolo, Gorini, Francesca, Gulino, Alessandro, Ranghetti, Pamela, Scarfò, Lydia, Scielzo, Cristina   +17 more
core   +1 more source

Predictors of response and rational combinations for the novel MCL‐1 inhibitor MIK665 in acute myeloid leukemia

Molecular Oncology, EarlyView.
This study characterizes the responses of primary acute myeloid leukemia (AML) patient samples to the MCL‐1 inhibitor MIK665. The results revealed that monocytic differentiation is associated with MIK665 sensitivity. Conversely, elevated ABCB1 expression is a potential biomarker of resistance to the treatment, which can be overcome by the combination ...
Joseph Saad, Rhiannon Newman, Elmira Khabusheva, Sofia Aakko, Eric Durand, Mahesh Tambe, Heikki Kuusanmäki, Alun Parsons, Juho J. Miettinen, Komal Kumar Javarappa, Ezgi June Olgac, Nemo Ikonen, Mika Kontro, Kimmo Porkka, Heiko Maacke, Janghee Woo, Ensar Halilovic, Caroline A. Heckman   +17 more
wiley   +1 more source

Intein‐based modular chimeric antigen receptor platform for specific CD19/CD20 co‐targeting

Molecular Oncology, EarlyView.
CARtein is a modular CAR platform that uses split inteins to splice antigen‐recognition modules onto a universal signaling backbone, enabling precise, scarless assembly without re‐engineering signaling domains. Deployed here against CD19 and CD20 in B‐cell malignancies, the design supports flexible multi‐antigen targeting to boost T‐cell activation and
Pablo Gonzalez‐Garcia, Noelia Moares, Wenjie Yi‐He, Rosa Luna‐Espejo, Ricardo Fernandez‐Cisnal, Javier Ocaña‐Cuesta, Juan P. Muñoz‐Miranda, Antonio Gabucio, Cecilia M. Fernandez‐Ponce, Francisco Garcia‐Cozar   +9 more
wiley   +1 more source

Biomaterial Strategies for Targeted Intracellular Delivery to Phagocytes

Advanced Functional Materials, EarlyView.
Phagocytes are essential to a functional immune system, and their behavior defines disease outcomes. Engineered particles offer a strategic opportunity to target phagocytes, harnessing inflammatory modulation in disease. By tuning features like size, shape, and surface, these systems can modulate immune responses and improve targeted treatment for a ...
Kaitlyn E. Woodworth, Neal I. Callaghan, Locke Davenport Huyer   +2 more
wiley   +1 more source

Study of serum antioxidant levels in patients with acute lymphocytic leukemia and chronic myelocytic leukemia before and after vincristine intake [PDF]

مجلة التربية والعلم, 2012
The study included the determination of the antioxidants levels of acute lymphocytic leukemia and chronic myelocytic leukemia patients in Mosul city (Before and after taking vincristine (Chemical drug)).
Noha altaalib
doaj   +1 more source